|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TOR4A |
Gene summary for TOR4A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TOR4A | Gene ID | 54863 |
| Gene name | torsin family 4 member A | |
| Gene Alias | C9orf167 | |
| Cytomap | 9q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NXH8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54863 | TOR4A | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.47e-04 | 1.59e-01 | 0.0155 |
| 54863 | TOR4A | HTA11_2487_2000001011 | Human | Colorectum | SER | 7.63e-16 | 5.31e-01 | -0.1808 |
| 54863 | TOR4A | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.57e-17 | 6.70e-01 | -0.0811 |
| 54863 | TOR4A | HTA11_78_2000001011 | Human | Colorectum | AD | 1.40e-05 | 3.09e-01 | -0.1088 |
| 54863 | TOR4A | HTA11_347_2000001011 | Human | Colorectum | AD | 8.06e-15 | 3.35e-01 | -0.1954 |
| 54863 | TOR4A | HTA11_411_2000001011 | Human | Colorectum | SER | 2.39e-06 | 8.99e-01 | -0.2602 |
| 54863 | TOR4A | HTA11_2112_2000001011 | Human | Colorectum | SER | 5.75e-06 | 6.77e-01 | -0.2196 |
| 54863 | TOR4A | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.25e-03 | 2.79e-01 | -0.1207 |
| 54863 | TOR4A | HTA11_83_2000001011 | Human | Colorectum | SER | 2.20e-06 | 4.47e-01 | -0.1526 |
| 54863 | TOR4A | HTA11_696_2000001011 | Human | Colorectum | AD | 5.16e-20 | 3.98e-01 | -0.1464 |
| 54863 | TOR4A | HTA11_866_2000001011 | Human | Colorectum | AD | 5.47e-12 | 2.48e-01 | -0.1001 |
| 54863 | TOR4A | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.54e-29 | 8.31e-01 | -0.059 |
| 54863 | TOR4A | HTA11_546_2000001011 | Human | Colorectum | AD | 1.66e-03 | 2.45e-01 | -0.0842 |
| 54863 | TOR4A | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.58e-05 | 2.92e-01 | -0.0179 |
| 54863 | TOR4A | HTA11_866_3004761011 | Human | Colorectum | AD | 2.34e-12 | 3.80e-01 | 0.096 |
| 54863 | TOR4A | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.51e-08 | 4.63e-01 | 0.0528 |
| 54863 | TOR4A | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.59e-04 | 5.55e-01 | 0.0131 |
| 54863 | TOR4A | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.71e-02 | 2.52e-01 | -0.0177 |
| 54863 | TOR4A | HTA11_6801_2000001011 | Human | Colorectum | SER | 8.02e-05 | 4.92e-01 | 0.0171 |
| 54863 | TOR4A | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.18e-03 | 2.46e-01 | 0.0338 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TOR4A | SNV | Missense_Mutation | c.415G>A | p.Glu139Lys | p.E139K | Q9NXH8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TOR4A | SNV | Missense_Mutation | novel | c.1169N>A | p.Arg390His | p.R390H | Q9NXH8 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TOR4A | SNV | Missense_Mutation | c.1105N>T | p.Arg369Trp | p.R369W | Q9NXH8 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TOR4A | SNV | Missense_Mutation | c.500N>G | p.Ala167Gly | p.A167G | Q9NXH8 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TOR4A | SNV | Missense_Mutation | c.1171N>A | p.Ala391Thr | p.A391T | Q9NXH8 | protein_coding | deleterious(0.04) | benign(0.358) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TOR4A | SNV | Missense_Mutation | c.382N>A | p.Ala128Thr | p.A128T | Q9NXH8 | protein_coding | tolerated(0.12) | benign(0.071) | TCGA-AG-3598-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TOR4A | SNV | Missense_Mutation | novel | c.1132N>A | p.Glu378Lys | p.E378K | Q9NXH8 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TOR4A | SNV | Missense_Mutation | novel | c.440G>A | p.Arg147His | p.R147H | Q9NXH8 | protein_coding | deleterious(0) | benign(0.336) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TOR4A | SNV | Missense_Mutation | novel | c.1176N>T | p.Glu392Asp | p.E392D | Q9NXH8 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TOR4A | SNV | Missense_Mutation | c.925N>T | p.Arg309Cys | p.R309C | Q9NXH8 | protein_coding | deleterious(0) | possibly_damaging(0.543) | TCGA-39-5028-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |